$5 million NIH grant to find causes of chronic pain after surgery | WashU Medicine
Study may lead to personalized prevention, management tools for post-operative pain
Related Articles
Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML
Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.
Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma
Long-term data from ZUMA-2 displayed durable responses with brexu-cel in relapsed/refractory mantle cell lymphoma.
Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate‐ and low‐risk prostate cancer
Although different adverse pathology definitions predict a higher risk of biochemical recurrence, metastasis, castrate-resistant prostate cancer, and prostate cancer–specific mortality, the absolute …
An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study.
James J. Harding, MD, reviews the ongoing phase 3 CheckMate 9DW trial, which is investigating nivolumab plus ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib…
Gender equity in oncology: Progress, challenges, and the path forward in urologic oncology and oncologic specialties
Despite the increasing number of women in medicine, gender disparities in leadership and career advancement, particularly in oncology, remain prominent. Addressing issues such as pay…
How a stem cell transplant changed the life — and blood — of a leukemia patient
A stem cell donor changed Laura Tiberi’s life after her leukemia diagnosis. Now she’s sharing hope and inspiration with other transplant recipients.
New Tool Can Help Improve Health Equity in Cancer Centers : Oncology Times
An abstract is unavailable.
Dostarlimab Plus Chemo Earns Positive CHMP Opinion for Expanded Indication in Advanced Endometrial Cancer
The EMA’s CHMP has recommended the approval of an expanded indication for dostarlimab plus chemotherapy in primary advanced/recurrent endometrial cancer.
Mosunetuzumab Plus Polatuzumab Vedotin Shows Improved Outcomes vs Rituximab Plus Polatuzumab Vedotin Among Patients With R/R Large B-Cell Lymphoma
Subcutaenous mosunetuzumab plus polatuzumab vedotin demonstrates improved efficacy and response rates compared with rituximab plus polatuzumab vedotin for patients with relapsed/refractory (R/R) LBCL, according to…
